Physician profile
David R Rivera
NPI 1013930536
$2,361.96
in general payments reported to CMS, 2019-2025
20 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.28 · 2020: $152 · 2021: $234 · 2022: $658 · 2023: $401 · 2024: $416 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $511.19 | 2019-2025 | Clareon, Argos, Eysuvis |
| Sun Pharmaceutical Industries INC. | $428.96 | 2020-2025 | Cequa |
| Biotissue Holdings INC. | $273.95 | 2019-2022 | |
| Oyster Point Pharma, INC. | $177.77 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $123.53 | 2022-2024 | Acuvue |
| Ocular Therapeutix, INC. | $120.90 | 2024 | Dextenza |
| Optovue, INC. | $94.37 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $89.24 | 2024 | Cystadrops |
| Allergan, INC. | $88.13 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $87.97 | 2022 | |
| Rayner Intraocular Lenses Limited | $67.93 | 2022-2025 | Omidria |
| Sight Sciences, INC. | $67.61 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $62.45 | 2019-2021 | |
| Omeros Corporation | $34.25 | 2021 | |
| Abbvie INC. | $33.32 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $25.59 | 2025 | Oxervate |
| Glaukos Corporation | $25.40 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $16.80 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $13.20 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.